image
Healthcare - Biotechnology - NASDAQ - US
$ 3.27
-0.909 %
$ 4.32 M
Market Cap
-0.21
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one GLTO stock under the worst case scenario is HIDDEN Compared to the current market price of 3.27 USD, Galecto, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one GLTO stock under the base case scenario is HIDDEN Compared to the current market price of 3.27 USD, Galecto, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one GLTO stock under the best case scenario is HIDDEN Compared to the current market price of 3.27 USD, Galecto, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart GLTO

image
$7.0$7.0$6.5$6.5$6.0$6.0$5.5$5.5$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
0 REVENUE
0.00%
-22.3 M OPERATING INCOME
44.22%
-21.4 M NET INCOME
44.10%
-18.6 M OPERATING CASH FLOW
49.55%
11.6 M INVESTING CASH FLOW
-47.83%
0 FINANCING CASH FLOW
0.00%
0 REVENUE
0.00%
-2.6 M OPERATING INCOME
63.40%
-2.53 M NET INCOME
62.42%
-2.44 M OPERATING CASH FLOW
50.59%
0 INVESTING CASH FLOW
0.00%
0 FINANCING CASH FLOW
0.00%
Balance Sheet Galecto, Inc.
image
Current Assets 16.8 M
Cash & Short-Term Investments 14.2 M
Receivables 881 K
Other Current Assets 1.78 M
Non-Current Assets 293 K
Long-Term Investments 0
PP&E 73 K
Other Non-Current Assets 220 K
82.74 %5.14 %10.41 %Total Assets$17.1m
Current Liabilities 1.2 M
Accounts Payable 377 K
Short-Term Debt 0
Other Current Liabilities 820 K
Non-Current Liabilities 104 K
Long-Term Debt 122 K
Other Non-Current Liabilities -18 K
28.98 %63.03 %9.38 %Total Liabilities$1.3m
EFFICIENCY
Earnings Waterfall Galecto, Inc.
image
Revenue 0
Cost Of Revenue 4.4 M
Gross Profit -4.4 M
Operating Expenses 17.9 M
Operating Income -22.3 M
Other Expenses -821 K
Net Income -21.4 M
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)0(4m)(4m)(18m)(22m)821k(21m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-135.42% ROE
-135.42%
-125.14% ROA
-125.14%
-139.96% ROIC
-139.96%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Galecto, Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)20192019202020202021202120222022202320232024202420252025
Net Income -21.4 M
Depreciation & Amortization 91 K
Capital Expenditures 0
Stock-Based Compensation 3.24 M
Change in Working Capital -2.67 M
Others 721 K
Free Cash Flow -18.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Galecto, Inc.
image
Wall Street analysts predict an average 1-year price target for GLTO of $10 , with forecasts ranging from a low of $10 to a high of $10 .
GLTO Lowest Price Target Wall Street Target
10 USD 205.81%
GLTO Average Price Target Wall Street Target
10 USD 205.81%
GLTO Highest Price Target Wall Street Target
10 USD 205.81%
Price
Max Price Target
Min Price Target
Average Price Target
161614141212101088664422Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 17
6. Ownership
Insider Ownership Galecto, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
11.6 K USD 3
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Galecto Reports First Quarter 2025 Operating and Financial Results BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced its operating and financial results for the quarter ended March 31, 2025. globenewswire.com - 1 month ago
Galecto Reports Full-Year 2024 Financial Results BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced its operating and financial results for the quarter and year ended December 31, 2024. globenewswire.com - 3 months ago
Galecto to Participate in Upcoming Investor Conferences BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and severe liver diseases, today announced that the Company management team will participate in the following upcoming investor conferences: globenewswire.com - 4 months ago
Galecto (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now Galecto (GLTO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. zacks.com - 7 months ago
Galecto Reports Third Quarter 2024 Financial Results -  Completed strategic review to focus on oncology and severe liver diseases -  Announced acquisition of global rights to BRM-1420, a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML from Bridge Medicines -  Appointed Dr. Amy Wechsler to the Board of Directors and Matthew Kronmiller as Executive Vice President of Strategy and Chief Business Officer BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and severe liver diseases, today reported financial results for the third quarter ended September 30, 2024. “The third quarter was a pivotal period for Galecto highlighted by the completion of a strategic review to prioritize oncology and liver diseases and subsequent acquisition of BRM-1420, a novel, dual ENL-YEATS, and FLT3 inhibitor for multiple genetic subsets of acute myeloid leukemia (AML) that further strengthens our existing portfolio of first-in-class small molecule agents,” said Dr. Hans Schambye, CEO of Galecto. globenewswire.com - 7 months ago
Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced the appointment of Dr. Amy Wechsler to its Board of Directors. Dr. Wechsler brings a unique combination of expertise and a proven track record of leadership in the healthcare industry. globenewswire.com - 8 months ago
Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that, following an intensive strategic review process, Galecto has determined to focus on cancer and liver disease, leveraging its existing clinical stage asset GB1211, which has shown positive results in non-small cell lung cancer (NSCLC) and decompensated cirrhosis clinical studies. Galecto further announced that it has bolstered its pipeline with the acquisition of the global rights to BRM-1420, a novel, first-in-class asset developed by Bridge Medicines, a company co-founded by Takeda. globenewswire.com - 8 months ago
Galecto Announces Reverse Stock Split BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that it will implement a 1-for-25 Reverse Stock Split of its common stock (the “Reverse Stock Split”), effective at 5:00 p.m. Eastern Time on Thursday, August 29, 2024. The Reverse Stock Split, which was approved by shareholders at the company's Annual Meeting of Stockholders on June 20, 2024, is primarily intended to bring the company into compliance with the minimum bid price requirement for maintaining its listing on The Nasdaq Capital Market. Beginning with the opening of trading on Friday, August 30, 2024, the company's common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under the existing symbol “GLTO” and a new CUSIP number 36322Q 206. globenewswire.com - 9 months ago
Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab An NCI-supported Phase 2 investigator-initiated trial at the Providence Cancer Institute in Portland, Oregon, has enrolled its first patient in a study exploring the combination of pembrolizumab (Keytruda®) and Galecto's GB1211, an oral galectin-3 inhibitor, in patients with metastatic melanoma and head and neck squamous cell carcinoma An NCI-supported Phase 2 investigator-initiated trial at the Providence Cancer Institute in Portland, Oregon, has enrolled its first patient in a study exploring the combination of pembrolizumab (Keytruda®) and Galecto's GB1211, an oral galectin-3 inhibitor, in patients with metastatic melanoma and head and neck squamous cell carcinoma globenewswire.com - 1 year ago
Galecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock? Galecto, Inc. (GLTO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 1 year ago
New Strong Buy Stocks for February 14th GLTO, LUMN, MORF, SFST and STOK have been added to the Zacks Rank #1 (Strong Buy) List on February 14, 2023. zacks.com - 1 year ago
What Makes Galecto, Inc. (GLTO) a New Strong Buy Stock Galecto, Inc. (GLTO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 1 year ago
8. Profile Summary

Galecto, Inc. GLTO

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 4.32 M
Dividend Yield 0.00%
Description Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
Contact 75 State Street, Boston, MA, 02109 https://galecto.com
IPO Date Oct. 29, 2020
Employees 5
Officers Ms. Lori C. Firmani Interim Chief Financial Officer Mr. Ulf J. Nilsson Ph.D. Co-Founder Mr. Matthew Kronmiller EVice President of Strategy & Chief Business Officer Dr. Hakon Leffler M.D., Ph.D. Co-Founder Dr. Hans T. Schambye M.D., Ph.D. Co-Founder, President, Chief Executive Officer & Director Mr. Garrett Winslow Esq. Senior Vice President, General Counsel & Corporate Secretary Prof. Tariq Sethi B.Sc., FRCP, M.A., M.D., Ph.D. Co-Founder